The Secondhand Aerosol Debate Revisited: What Five Years of Research Have Clarified

In 2020, the question of whether secondhand e-cigarette aerosol posed a health risk to bystanders was largely unanswered. The studies were small, the methods were inconsistent, and the conclusions ranged from 'no identified risk' (Public Health England) to 'potentially harmful, avoid exposure' (WHO). Five years later, a substantial body of research has accumulated—chamber studies measuring airborne toxicants under controlled conditions, real-world monitoring in vape shops and homes, biomarker studies measuring nicotine metabolites in non-vaping bystanders, and systematic reviews synthesizing the evidence. The findings have clarified some questions, complicated others, and consistently reinforced the central message: secondhand vaping aerosol is not harmless, but it's dramatically less harmful than secondhand tobacco smoke. The policy implications of that finding remain contested.

The exposure data is the most consistent and reassuring finding. Studies that measure airborne concentrations of toxicants in rooms where vaping occurs consistently find levels that are orders of magnitude lower than in rooms where smoking occurs, and in many cases comparable to background levels in buildings with no smoking or vaping. A 2024 systematic review of 30 chamber and field studies found that airborne nicotine, particulate matter, carbonyl compounds, and volatile organic compounds were 90–99% lower in vaping environments than in smoking environments. The few toxicants that were detectable at elevated levels—primarily ultrafine particles and nicotine—were within occupational exposure limits and substantially below levels associated with health effects in epidemiological studies. The exposure data supports the conclusion that secondhand vaping aerosol, while not absent, is at levels where health effects to bystanders are unlikely to be detectable even in large epidemiological studies.

The biomarker data tells a consistent story. Studies that measure cotinine (a nicotine metabolite) in the urine or saliva of non-vaping bystanders find that exposure to secondhand vapor produces measurable nicotine absorption—but at levels that are a small fraction (typically 5–10%) of the absorption from equivalent secondhand smoke exposure. The clinical significance of this low-level nicotine absorption is uncertain: the levels are below those associated with cardiovascular or developmental effects in the available literature, but the long-term consequences of chronic low-level exposure over years or decades are unknown. The biomarker data confirms that bystanders are exposed to nicotine from secondhand vapor—contrary to some early claims that exhaled aerosol contained no nicotine—but the exposure is quantitatively small and of uncertain health significance.

The particulate matter question has been partially resolved. Early studies raised concern about the ultrafine particles in e-cigarette aerosol, noting that particle concentrations in some vaping environments approached those in smoking environments. Subsequent research clarified that the particle composition is fundamentally different: cigarette smoke particles contain the toxicants associated with combustion (polycyclic aromatic hydrocarbons, heavy metals, carbonaceous material), while e-cigarette aerosol particles consist primarily of liquid droplets of propylene glycol and vegetable glycerin that evaporate within seconds, leaving minimal residue. The particle count (number of particles per unit volume) may be comparable between smoking and vaping environments, but the particle toxicity is not. This distinction—between particle count and particle composition—is one of the most important and least-understood aspects of the secondhand aerosol debate, and it's often obscured in public communications that report particle counts without composition context.

The vulnerable-population question remains the most significant area of uncertainty. For healthy adults, the evidence suggests that secondhand vaping aerosol at typical exposure levels poses minimal acute health risk, and the chronic risk—while uncertain—is likely to be small. For vulnerable populations—people with asthma, COPD, or cardiovascular disease; pregnant women; infants and children—the risk is less clear. The limited evidence available suggests that vaping aerosol can trigger respiratory symptoms in some people with asthma and that nicotine exposure during pregnancy and early childhood, even at low levels, may have developmental effects. The precautionary principle, applied to vulnerable populations, argues for avoiding exposure even if the absolute risk is uncertain and probably small. The practical implication is nuanced: vaping indoors around healthy adults is unlikely to cause harm; vaping around vulnerable individuals, particularly in enclosed spaces with poor ventilation, should be avoided out of an abundance of caution.

The policy implications of the evidence are less clear than either side of the debate acknowledges. The evidence does not support treating vaping and smoking identically for indoor air quality regulation—the exposure levels, toxicant profiles, and health risks are too different to justify identical treatment. But the evidence also does not support treating vaping as indistinguishable from breathing air—there is real exposure, real nicotine absorption, and real uncertainty about long-term effects. A reasonable policy framework would: prohibit vaping where smoking is prohibited in spaces where vulnerable populations are concentrated (schools, healthcare facilities, childcare settings); permit venue operators to set their own policies in spaces where only healthy adults are present (bars, restaurants, workplaces); require clear signage so that both vapers and non-vapers can make informed choices; and invest in continued research on the health effects of chronic low-level exposure to secondhand aerosol. This framework is more nuanced than the binary 'ban vaping indoors or don't' that dominates the policy debate. But it's consistent with the evidence—and with the principle that policy should be calibrated to risk rather than applied uniformly across products with different risk profiles.